GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tibet Aim Pharm Inc (SZSE:002826) » Definitions » Current Ratio

Tibet Aim Pharm (SZSE:002826) Current Ratio : 2.85 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Tibet Aim Pharm Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Tibet Aim Pharm's current ratio for the quarter that ended in Mar. 2024 was 2.85.

Tibet Aim Pharm has a current ratio of 2.85. It generally indicates good short-term financial strength.

The historical rank and industry rank for Tibet Aim Pharm's Current Ratio or its related term are showing as below:

SZSE:002826' s Current Ratio Range Over the Past 10 Years
Min: 1.79   Med: 2.85   Max: 5.08
Current: 2.85

During the past 10 years, Tibet Aim Pharm's highest Current Ratio was 5.08. The lowest was 1.79. And the median was 2.85.

SZSE:002826's Current Ratio is ranked better than
69.42% of 1076 companies
in the Drug Manufacturers industry
Industry Median: 1.87 vs SZSE:002826: 2.85

Tibet Aim Pharm Current Ratio Historical Data

The historical data trend for Tibet Aim Pharm's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tibet Aim Pharm Current Ratio Chart

Tibet Aim Pharm Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.37 2.22 2.06 3.65 2.20

Tibet Aim Pharm Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.33 2.25 2.40 2.86 2.85

Competitive Comparison of Tibet Aim Pharm's Current Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Aim Pharm's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tibet Aim Pharm's Current Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tibet Aim Pharm's Current Ratio distribution charts can be found below:

* The bar in red indicates where Tibet Aim Pharm's Current Ratio falls into.



Tibet Aim Pharm Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Tibet Aim Pharm's Current Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Current Ratio (A: Dec. 2022 )=Total Current Assets (A: Dec. 2022 )/Total Current Liabilities (A: Dec. 2022 )
=575.009/261.914
=2.20

Tibet Aim Pharm's Current Ratio for the quarter that ended in Mar. 2024 is calculated as

Current Ratio (Q: Mar. 2024 )=Total Current Assets (Q: Mar. 2024 )/Total Current Liabilities (Q: Mar. 2024 )
=505.682/177.738
=2.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tibet Aim Pharm  (SZSE:002826) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Tibet Aim Pharm Current Ratio Related Terms

Thank you for viewing the detailed overview of Tibet Aim Pharm's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Tibet Aim Pharm (SZSE:002826) Business Description

Traded in Other Exchanges
N/A
Address
No. 6, Linqionggang Road, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Tibet Aim Pharm Inc is the pharmaceutical company based in China. It is mainly engaged in the research and development, production and sales of chemical drugs and proprietary Chinese medicines for common chronic disease such as diabetes and cardiovascular disease as well as medicines for gynecology and obstetrics. The company's products offering includes miglitol tablets, gualoupi injection, nalmefene hydrochloride injection, carbetocin injection; hongjin xiaojie tablets and aceclofenac enteric-coated tablets. The company also expanded its products in the treatment of antibiotic, antiallergic and digestive system.
Executives
Peng Hui Director
Pang Guo Qiang Directors, executives
Li Qian Jin Securities Affairs Representative
Liu Hang Supervisors

Tibet Aim Pharm (SZSE:002826) Headlines

No Headlines